Date	e:2023/03/	16	
	r Name: Xin Zh		
Mar	nuscript Title:_ Effect of the	N ⁶ -methyladenosine reade	er IGF2BP3 on the malignant progression in glioma
Mar	nuscript number (if known):		
rela part to to rela The mar The to to	ted to the content of your makes whose interests may be ransparency and does not not tionship/activity/interest, it following questions apply to the content only. author's relationships/activity author, even if that medical	nanuscript. "Related" mean affected by the content of ecessarily indicate a bias. It is preferable that you do so the author's relationship wities/interests should be <u>donsion</u> , you should declare a tion is not mentioned in the	s/activities/interests as they relate to the <u>current</u> <u>efined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive ne manuscript.
	em #1 below, report all sup time frame for disclosure is	-	in this manuscript without time limit. For all other items
		Name all entities with	Specifications/Comments
		whom you have this relationship or indicate	(e.g., if payments were made to you or to your institution)
		none (add rows as needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present	X None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time from a neet	2C months
2	Grants or contracts from	Time frame: past X None	50 Months
_	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	
		1	1

lectures, p speakers l manuscrip education	ot writing or al events		
6 Payment f testimony		XNone	
	or attending and/or travel	XNone	
8 Patents pl	lanned, issued or	XNone	
pending			
	ion on a Data	XNone	
Advisory E	onitoring Board or		
	p or fiduciary role	X None	
	oard, society,		
committe	e or advocacy id or unpaid		
	tock options	XNone	
1	f equipment,	XNone	
	drugs, medical		
services	fts or other		
	ncial or non-	X None	
financial i	nterests		
Please summa	arize the above co	nflict of interest in the foll	owing box:

None		

Date	e:2023/03/	16	
	Name: Sheng		
Man	uscript Title:_ Effect of the	N ⁶ -methyladenosine reade	er IGF2BP3 on the malignant progression in glioma
Man	uscript number (if known):		
relat parti to tr relat The man The to th med	ted to the content of your makes whose interests may be an sparency and does not not ionship/activity/interest, it following questions apply to uscript only. author's relationships/activity e epidemiology of hyperterication, even if that medical em #1 below, report all supports whose ionships is a support all supports and interest in the support all supports in the supports	nanuscript. "Related" mean affected by the content of ecessarily indicate a bias. It is preferable that you do so the author's relationship wities/interests should be dension, you should declare a tion is not mentioned in the	s/activities/interests as they relate to the <u>current</u> lefined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
the t	ime frame for disclosure is	the past 36 months. Name all entities with	Specifications/Comments
		whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	l planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

lectures, p speakers l manuscrip education	ot writing or al events		
6 Payment f testimony		XNone	
	or attending and/or travel	XNone	
8 Patents pl	lanned, issued or	XNone	
pending			
	ion on a Data	XNone	
Advisory E	onitoring Board or		
	p or fiduciary role	X None	
	oard, society,		
committe	e or advocacy id or unpaid		
	tock options	XNone	
1	f equipment,	XNone	
	drugs, medical		
services	fts or other		
	ncial or non-	X None	
financial i	nterests		
Please summa	arize the above co	nflict of interest in the foll	owing box:

None		

Date	e:2023/03/	´16	
	r Name:Ju Yu_		
Mar	nuscript Title:_ Effect of the	N ⁶ -methyladenosine read	er IGF2BP3 on the malignant progression in glioma
Mar	nuscript number (if known):		
rela part to to rela The mar The to to	ted to the content of your naties whose interests may be ransparency and does not not it it is following questions apply to muscript only. author's relationships/active epidemiology of hypertendication, even if that medications	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias. It is preferable that you do to the author's relationship vities/interests should be on nsion, you should declare ation is not mentioned in the	os/activities/interests as they relate to the <u>current</u> defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
	time frame for disclosure is	-	in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as needed)	
		Time frame: Since the initia	al planning of the work
1	All support for the present	X None	in planning of the work
1	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	t 36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated in item #1 above).		
3	Royalties or licenses	X None	
3	Noyalties of ficelises		
4	Consulting fees	XNone	
	_		

lectures, p speakers l manuscrip education	ot writing or al events		
6 Payment f testimony		XNone	
	or attending and/or travel	XNone	
8 Patents pl	lanned, issued or	XNone	
pending			
	ion on a Data	XNone	
Advisory E	onitoring Board or		
	p or fiduciary role	X None	
	oard, society,		
committe	e or advocacy id or unpaid		
	tock options	XNone	
1	f equipment,	XNone	
	drugs, medical		
services	fts or other		
	ncial or non-	X None	
financial i	nterests		
Please summa	arize the above co	nflict of interest in the foll	owing box:

None		

Date	e:2023/03/	16	
You	Name:Chung	ang Dai	
Man	uscript Title:_ Effect of the	N ⁶ -methyladenosine read	er IGF2BP3 on the malignant progression in glioma
	uscript number (if known):		
relat part to tr	ted to the content of your nies whose interests may be	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias.	relationships/activities/interests listed below that are ns any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	following questions apply to uscript only.	o the author's relationship	os/activities/interests as they relate to the <u>current</u>
to th		nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript.
	em #1 below, report all sup time frame for disclosure is	· ·	l in this manuscript without time limit. For all other items,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	I planning of the work
1	All support for the present	X None	in presiming of the front
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.		
		Time frame: past	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

lectures, p speakers l manuscrip education	ot writing or al events		
6 Payment f testimony		XNone	
	or attending and/or travel	XNone	
8 Patents pl	lanned, issued or	XNone	
pending			
	ion on a Data	XNone	
Advisory E	onitoring Board or		
	p or fiduciary role	X None	
	oard, society,		
committe	e or advocacy id or unpaid		
	tock options	XNone	
1	f equipment,	XNone	
	drugs, medical		
services	fts or other		
	ncial or non-	X None	
financial i	nterests		
Please summa	arize the above co	nflict of interest in the foll	owing box:

None		

Date	e:2023/03/	16	
	r Name:Suji Ya		
Man	uscript Title:_ Effect of the	N ⁶ -methyladenosine reade	er IGF2BP3 on the malignant progression in glioma
Man	nuscript number (if known):		
relate to trelate man The to the med	ted to the content of your name ies whose interests may be cansparency and does not not it in the interest, it following questions apply the interest only. author's relationships/active epidemiology of hyperterication, even if that medical	nanuscript. "Related" mean affected by the content of ecessarily indicate a bias. It is preferable that you do so to the author's relationship wities/interests should be do nsion, you should declare a tion is not mentioned in the	es/activities/interests as they relate to the <u>current</u> <u>lefined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
		Name all entities with whom you have this	Specifications/Comments (e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initia	l planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials, medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	X None	
_	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	X None	
	,		
4	Consulting fees	XNone	

	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
10	Advisory Board	V. Nana	
10	Leadership or fiduciary role in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	·		
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	X None	
13	financial interests		
Plea	ase summarize the above co	nflict of interest in the foll	owing box:

None			

Date	e:2023/03/	16	
	r Name: Gang		
Mar	nuscript Title:_ Effect of the	N ⁶ -methyladenosine read	er IGF2BP3 on the malignant progression in glioma
Mar	nuscript number (if known):		
rela part to t	ted to the content of your naties whose interests may be	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias.	relationships/activities/interests listed below that are ns any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	following questions apply to nuscript only.	o the author's relationship	os/activities/interests as they relate to the <u>current</u>
to t	•	nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript.
	em #1 below, report all sup time frame for disclosure is	•	I in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	I planning of the work
_		Time frame: Since the initia	n planning of the work
1	All support for the present manuscript (e.g., funding,	XNone	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	t 36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	X None	
7	Consulting ICCs	NOTIC	

	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
10	Advisory Board	V. Nana	
10	Leadership or fiduciary role in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	·		
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	X None	
13	financial interests		
Plea	ase summarize the above co	nflict of interest in the foll	owing box:

None			

Date	e:2023/03/	16	
	· Name: Chao S		
Man	uscript Title:_ Effect of the	N ⁶ -methyladenosine reade	er IGF2BP3 on the malignant progression in glioma
Man	uscript number (if known):		
relat parti to tr relat The man The to th	ted to the content of your management ies whose interests may be an	nanuscript. "Related" mean affected by the content of ecessarily indicate a bias. It is preferable that you do so the author's relationship wities/interests should be <u>do</u> nsion, you should declare a tion is not mentioned in the	s/activities/interests as they relate to the <u>current</u> <u>efined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
	ime frame for disclosure is	-	•
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
10	Advisory Board	V. Nana	
10	Leadership or fiduciary role in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	·		
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	X None	
13	financial interests		
Plea	ase summarize the above co	nflict of interest in the foll	owing box:

None			